Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors.
Acta Pharm Sin B
; 10(8): 1476-1491, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32963944
BLI, biolayer interferometry technology; CHX, cycloheximide; DUBs, deubiquitinating enzymes; Deubiquitination; EMT, epithelial-mesenchymal transition; EdU, 5-ethynyl-2'-deoxyuridine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Gastric cancer; IC50, half maximal inhibitory concentration; Kd, dissociation constant; LSD1, lysine specific demethylase 1; MG132, proteasome inhibitor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazoliumbromide; NSCLC, non-small cell lung cancer; Tris, 2-amino-2-(hydroxymethyl)-1,3-propanediol; USP28 inhibitors; USP28, ubiquitin specific peptidase 28; USP7, ubiquitin specific peptidase 7; Ub, ubiquitin; Ub-AMC, ubiquitin-7-amido-4-methylcoumarin; [1,2,3]Triazolo[4,5-d]pyrimidine derivatives
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Acta Pharm Sin B
Año:
2020
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Países Bajos